Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 5/20 | 0.47 |
| ▸ | ATR | Q13535 | 1/20 | 0.47 |
| ▸ | STK17B | O94768 | 1/20 | 0.46 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.43 |
| ▸ | KCNQ3 | O43525 | 3/20 | 0.42 |
| ▸ | KCNQ2 | O43526 | 3/20 | 0.42 |
| ▸ | KCNQ5 | Q9NR82 | 3/20 | 0.42 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.42 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31378805 | 0.83 | KCNQ3 (0.53) | MAPKAPK2ATRNAMPTCYP17A1KCNQ3 | |
| SCHEMBL535403 | 0.83 | KCNQ3 (0.53) | MAPKAPK2ATRNAMPTCYP17A1KCNQ3 | |
| SCHEMBL12517613 | 0.83 | NAMPT (0.45) | MAPKAPK2ATRNAMPTCYP17A1CA12 | |
| SCHEMBL1548181 | 0.83 | MAPKAPK2 (0.47) | MAPKAPK2ATRNAMPTCYP17A1PSMB8 | |
| SCHEMBL25547892 | 0.81 | CYP17A1 (0.44) | MAPKAPK2ATRNAMPTCYP17A1CA12 | |
| SCHEMBL1010435 | 0.81 | ATR (0.46) | MAPKAPK2ATRSTK17BSTK17ANAMPT | |
| SCHEMBL9951442 | 0.80 | ATR (0.48) | MAPKAPK2ATRNAMPTCYP17A1CA12 | |
| SCHEMBL21885914 | 0.80 | CYP17A1 (0.45) | MAPKAPK2ATRNAMPTCYP17A1PSMB8 | |
| SCHEMBL25547875 | 0.80 | CYP17A1 (0.45) | MAPKAPK2ATRNAMPTCYP17A1CA12 | |
| SCHEMBL12902766 | 0.80 | ATR (0.45) | MAPKAPK2ATRNAMPTCYP17A1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11980609-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-05-14 | — | — | US | disclosed |
| EP-4337641-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2024-03-20 | — | — | EP | disclosed |
| CN-117295717-A | LPA receptor antagonists and uses thereof | 吉利德科学公司 | 2023-12-26 | — | — | CN | disclosed |
| US-20230310400-A9 | SYNTHESIS OF SMALL MOLECULE HISTONE DEACETYLASE 6 DEGRADERS, COMPOUNDS FORMED THEREBY, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-10-05 | — | — | US | disclosed |
| US-20230295123-A1 | NOVEL IMIDAZOLE-PYRAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-09-21 | — | — | US | disclosed |
| EP-4208454-A1 | IMIDAZOLE-PYRAZOLE DERIVATIVES WITH ANTI-BACTERIAL PROPERTIES | F. Hoffmann-La Roche AG (CH) | 2023-07-12 | — | — | EP | disclosed |
| CN-115989227-A | Imidazole-pyrazole derivatives having antibacterial properties | 豪夫迈·罗氏有限公司 | 2023-04-18 | — | — | CN | disclosed |
| US-20220411405-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2022-12-29 | — | — | US | disclosed |
| US-20220411405-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2022-12-29 | — | — | US | disclosed |
| WO-2022240879-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2022-11-17 | — | — | WO | disclosed |
| WO-2022049011-A1 | IMIDAZOLE-PYRAZOLE DERIVATIVES WITH ANTI-BACTERIAL PROPERTIES | F. HOFFMANN-LA ROCHE AG (CH) | 2022-03-10 | — | — | WO | disclosed |
| US-11059815-B2 | Synthesis of small molecule histone deacetylase 6 degraders, compounds formed thereby, and pharmaceutical compositions containing them | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2021-07-13 | — | — | US | disclosed |
| US-20200190079-A1 | SYNTHESIS OF SMALL MOLECULE HISTONE DEACETYLASE 6 DEGRADERS, COMPOUNDS FORMED THEREBY, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310400-A9 | SYNTHESIS OF SMALL MOLECULE HISTONE DEACETYLASE 6 DEGRADERS, COMPOUNDS FORMED THEREBY, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | HDAC1, HDAC6, HDAC3 | MAPKAPK2 1951/4885ATR 1207/4885STK17B 2201/4885 |
| US-20200190079-A1 | SYNTHESIS OF SMALL MOLECULE HISTONE DEACETYLASE 6 DEGRADERS, COMPOUNDS FORMED THEREBY, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | HDAC1, HDAC6, HDAC3 | MAPKAPK2 1951/4885ATR 1207/4885STK17B 2201/4885 |
| US-20230295123-A1 | NOVEL IMIDAZOLE-PYRAZOLE DERIVATIVES | CYP3A7, NISCH, ARG1 | MAPKAPK2 2620/4885ATR 2762/4885STK17B 575/4885 |
| US-11980609-B2 | LPA receptor antagonists and uses thereof | LPAR1, LPAR2, LPAR4 | MAPKAPK2 1024/4885ATR 3568/4885STK17B 1256/4885 |
| US-11059815-B2 | Synthesis of small molecule histone deacetylase 6 degraders, compounds formed thereby, and pharmaceutical compositions containing them | HDAC1, HDAC6, HDAC3 | MAPKAPK2 1951/4885ATR 1207/4885STK17B 2201/4885 |
| US-20220411405-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR1, LPAR2, LPAR4 | MAPKAPK2 1024/4885ATR 3568/4885STK17B 1256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.